Several recognized subtypes possess additional layers of heterogeneity that include cytogenetic factors and age of onset, which make it difficult to define unique drug targets as candidates that might induce long-term remissions such as BCR-ABL in chronic myeloid leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.